A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function
Latest Information Update: 01 Feb 2024
At a glance
- Drugs Epetraborole (Primary)
- Indications Nontuberculous mycobacterium infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AN2 Therapeutics
Most Recent Events
- 11 Oct 2023 According to an AN2 Therapeutics media release, company will be presented data from this trial at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.
- 13 Jul 2022 Status changed from recruiting to completed.
- 10 May 2022 According to an AN2 Therapeutics media release, topline results are expected in the second half of 2022.